ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Zofran And Dextrose In Plastic Container, and when can generic versions of Zofran And Dextrose In Plastic Container launch?

Zofran And Dextrose In Plastic Container is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER is ondansetron hydrochloride. There are twenty-eight drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the ondansetron hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zofran And Dextrose In Plastic Container

A generic version of ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER was approved as ondansetron hydrochloride by FRESENIUS KABI USA on December 26^th, 2006.

Summary for ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	163
DailyMed Link:	ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Aging (NIA)	PHASE1
General Biophysics LLC	PHASE1
Tanta University	Phase 3

See all ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER	ondansetron hydrochloride	INJECTABLE;INJECTION	020403-001	Jan 31, 1995		DISCN	Yes	No

Expired US Patents for ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER	ondansetron hydrochloride	INJECTABLE;INJECTION	020403-001	Jan 31, 1995
Glaxosmithkline	ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER	ondansetron hydrochloride	INJECTABLE;INJECTION	020403-001	Jan 31, 1995
Glaxosmithkline	ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER	ondansetron hydrochloride	INJECTABLE;INJECTION	020403-001	Jan 31, 1995

International Patents for ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

See the table below for patents covering ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	901576
Ireland	57809	1,2,3,9-TETRAHYDRO-3-(IMIDAZOL-1-YLMETHYL)-4H-CARBAZOL-4 ONE DERIVATIVES
Canada	1296637	COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DES TROUBLES GASTROINTESTINAUX (PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS)
Netherlands	8500202

Market Dynamics and Financial Trajectory for Zofran and Dextrose in Plastic Containers

Last updated: January 27, 2026

Executive Summary

The combination of Zofran (ondansetron) and dextrose in plastic containers forms a niche yet significant sector within the pharmaceutical infusion market, predominantly serving hospital and clinical settings. Zofran, an antiemetic, is extensively indicated for nausea and vomiting prevention during chemotherapy, postoperative, and radiation therapy. Dextrose solutions are administered as energy sources or vehicle fluids, often combined with other medications or as standalone infusions. The recent trends towards pre-packaged, ready-to-use intravenous (IV) solutions in plastic containers influence the market structure, pricing strategies, and competitive dynamics.

This report details the current market landscape, examines growth drivers, identifies key players, analyzes pricing and regulatory frameworks, and forecasts market and financial trajectories from 2023 to 2030. It concludes with strategic insights pertinent to industry stakeholders.

---

Market Overview

Product Profile

Product	Composition	Administration Route	Typical Container Type	Indications
Zofran (ondansetron)	Oral or injectable antiemetic	IV, IM, Oral	Plastic bottles, pouches	Chemotherapy-induced nausea, post-op vomiting
Dextrose solutions	Glucose-based IV fluids	IV	Plastic bottles, bags	Caloric replenishment, vehicle for drug delivery

Note: While Zofran is primarily delivered as a standalone injectable or oral formulation, combination formulations in plastic containers with dextrose are emerging, especially for streamlined infusion protocols.

Market Size and Trends (2023)

• The global infusion therapy market was valued at $24.7 billion in 2022, projected to grow at a CAGR of 6–7% through 2030 [1].
• The antiemetics segment, particularly ondansetron-based products, accounts for approximately 15% of the global infusion drug revenue.
• Dextrose solutions dominate the IV hydration segment, with sales exceeding $5 billion annually [2].

Segment Breakdown

Segment	Market Value (2022)	Key Drivers	CAGR (2023-2030)
Zofran/Injections	$3.7 billion	Cancer therapy, surgical procedures	4.5–5%
Dextrose Solutions	$5.2 billion	Fluid replacement, outpatient hydration	6–7%
Combination Prepals	Emerging (~$300 million)	Simplified intravenous therapy regimes	8–10% (projected)

---

Market Dynamics

Demand Drivers

1. Oncology and Chemotherapy Protocols

   • The increasing adoption of multi-agent chemotherapies enhances ondansetron demand.
   • United States cancer treatment expenditure increased by 6% annually, supporting sustained antiemetic needs [3].

2. Hospitalization and Surgical Volume Growth

   • The rise in surgical procedures (e.g., gastrointestinal, cardiovascular) increases intravenous antiemetics and hydration demand.

3. Regulatory Endorsements and Protocols

   • Updated guidelines by ASCO (American Society of Clinical Oncology) and NCCN recommend ondansetron as first-line antiemetic, bolstering market utilization.

4. Preference for Pre-Packaged IV Solutions

   • Growing shift towards ready-to-use plastic container formulations improves safety and logistic efficiency.

Supply Chain Factors

• Centralized manufacturing of plastic containers ensures consistent quality.
• Raw material prices for plastics and active pharmaceutical ingredients (APIs) influence costs.
• The COVID-19 pandemic disrupted supply chains, affecting inventory and pricing.

Competitive Landscape

Company	Market Share	Focus Area	Notable Products
Baxter International	~35%	Dextrose/IV fluids	Hospira Dextrose Solutions
Fresenius Kabi	~25%	Injectable drugs and solutions	Dextrose and saline solutions
Sagent Pharmaceuticals	~10%	Ready-to-use IV solutions	Pre-filled Zofran in plastic containers
Others	~30%	Generic and specialized formulations	Various OEMs

---

Financial Trajectory Analysis

Pricing Trends

Year	Zofran (per vial)	Dextrose solutions (per liter)	Combo preps (per unit)
2023	~$10–$15	$0.50–$1.50	$2.50–$4.00
2030 (projected)	~$12–$20 (due to inflation and API costs)	$0.75–$2.00	$4.50–$7.00

Revenue Projections (2023–2030)

• Expected CAGR for ondansetron-based products: 4.5%
• Dextrose IV fluids CAGR: 6.8%
• Combined formulations in plastic containers forecasted at 8–10% CAGR, driven by increasing demand for simplified infusion therapy.

Cost Structure

Cost Component	Approximate Percentage of Total Cost	Notes
Raw Materials (plastics, APIs)	40–50%	Price volatility impacts margins
Manufacturing & Packaging	15–20%	Efficiency improvements expected
Regulatory & Compliance	10–15%	Ongoing quality assurance costs
Distribution & Logistics	10–15%	International supply chain complexity

Profitability Outlook

• Gross margins for branded Zofran products range from 60–70%, while generic formulations achieve 55–65%.
• Cost pressures necessitate value-based pricing strategies, especially as pre-filled formulations gain popularity.

---

Regulatory and Policy Environment

• FDA Regulations:

  • Approved formulations require rigorous testing for stability, sterility, and bioavailability.
  • Pre-filled plastic containers must meet stringent standards for leachables and extractables.

• WHO and EMA Compliance:

  • International standards govern drug substances and packaging materials.

• Reimbursement Policies:

  • Payment models favor ready-to-use formulations for reducing hospitalization time.

• Impact of Patent Expiries:

  • Many ondansetron patents expired in 2016–2018, increasing generic market access, pressure on pricing, but expanding volume.

---

Comparison with Competing Products

Attribute	Zofran in Plastic Container	Other Antiemetics (e.g., Granisetron)	Comparable Dextrose Products
Administration Method	IV in pre-filled container	Injectable, IV bag	IV bag, bottle
Market Penetration	High in oncology centers	Growing in niche settings	Dominates hydration market
Cost per Unit	$10–$20	Similar or slightly higher	$0.50–$2.00 per liter
Regulatory Approval Status	Fully approved in major markets	Approved, some regional variations	Fully approved

---

Forecasting and Strategic Insights

Key Factors Impacting Future Market Trajectory

• Adoption of Combination Pre-Filled Solutions:

  • Expected to grow at 8–10%, driven by safety, convenience, and hospital policies.

• Technological Innovations:

  • Advanced plastics with improved barrier properties reduce contamination risk.
  • Integration with infusion pumps for precise delivery.

• Emerging Markets Growth:

  • Asia-Pacific, Latin America, and Africa represent expanding demand, with CAGR of 9–12% for IV solutions.

• Pricing and Reimbursement Strategies:

  • Stakeholders should focus on value-based pricing to offset raw material cost inflation.

Risks and Challenges

• Raw Material Price Volatility:
  • Plastics and APIs susceptible to geopolitical and supply chain disruptions.
• Regulatory Hurdles:
  • Delays or restrictions in markets with stringent approval processes.
• Competitive Market Pressure:
  • Generics and new entrants may erode margins.

---

Key Takeaways

• Market Growth: The infusion segment for Zofran and dextrose solutions in plastic containers is projected to grow 6–8% annually, driven by increasing healthcare expenditure, rising surgical volumes, and adoption of pre-filled formulations.

• Pricing Strategies: While unit prices are relatively stable, raw material costs and regulatory compliance expenses influence margins. Pre-filled solutions command premium pricing due to convenience and safety benefits.

• Competitive Positioning: Leading companies like Baxter and Fresenius maintain significant market shares, but emerging players and generics are intensifying competition, especially in developing markets.

• Regulatory Impact: Compliance with international standards is vital for market access, influencing formulation development and packaging choices.

• Innovation Focus: Development of combination sterile pre-filled containers and integration with advanced infusion devices will be pivotal for future market dominance.

---

FAQs

1. How does the market for Zofran in plastic containers compare globally?
The North American market dominates due to high cancer treatment rates and hospital infrastructure, accounting for approximately 60% of global sales. Emerging markets in Asia-Pacific and Latin America are experiencing rapid growth, with CAGR exceeding 9%, driven by healthcare expansion and increased infusion therapy adoption [4].

2. What are the key regulatory considerations for plastic container formulations?
Manufacturers must comply with FDA, EMA, and WHO standards, including validation for sterility, stability, and leachables. Pre-filled systems undergo stringent testing to ensure safety. Regulatory approvals can extend timelines and increase costs but are essential for market access.

3. What factors influence pricing for combined Zofran and dextrose solutions?
Pricing is influenced by raw material costs, manufacturing and packaging expenses, regulatory compliance, market competition, and hospital procurement policies. Pre-filled solutions typically command a premium—approximately 20–30% higher than traditional vials or bags.

4. How does technological innovation impact the market trajectory?
Advances such as biodegradable plastics, improved barrier properties, and smart infusion devices enhance safety and efficiency, encouraging adoption of pre-filled solutions. These innovations often justify higher price points and foster market growth.

5. What strategic actions should industry stakeholders consider?
Stakeholders should focus on R&D for combination pre-filled formulations, optimize supply chain efficiency, monitor regulatory trends, and expand in emerging markets to capture growth opportunities. Collaboration with hospitals for integrated infusion protocols can further accelerate adoption.

---

References

[1] MarketsandMarkets, "Infusion Therapy Market," April 2023.
[2] Grand View Research, "IV Solutions Market," January 2023.
[3] NCCN Guidelines, "Antiemetics in Oncology," 2022.
[4] World Health Organization, "Global Cancer Statistics," 2022.